Headlines
Novo CEO Says Its Bid for Metsera Is Higher
Published by Global Banking & Finance Review®
Posted on November 6, 2025
1 min readLast updated: January 21, 2026
Add as preferred source on GoogleGlobal Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on November 6, 2025
1 min readLast updated: January 21, 2026
Add as preferred source on GoogleNovo Nordisk CEO Mike Doustdar announced a higher bid for Metsera than Pfizer's, amid legal disputes over the acquisition terms.
NEW YORK (Reuters) -Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc., which has sued both Metsera and Novo over the terms of their rival deal.
"As of today, our bid is higher, and our message to Pfizer is that if they would like to buy the company, then put your hand in the pocket and bid higher," Doustdar said.
(Reporting by Bhargav Acharya)
A merger is a business combination where two companies join to form a single entity, often to increase market share, reduce competition, or achieve synergies.
An acquisition occurs when one company purchases another company, gaining control over its assets and operations, often to expand its market presence or capabilities.
A bid in finance refers to an offer made by an investor or company to purchase a security or asset at a specified price.
Explore more articles in the Headlines category
